🇺🇸 Glucosamine/Chondroitin in United States

4,049 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 4,049

Most-reported reactions

1. Fatigue — 642 reports (15.86%)
2. Diarrhoea — 442 reports (10.92%)
3. Nausea — 410 reports (10.13%)
4. Drug Ineffective — 403 reports (9.95%)
5. Headache — 400 reports (9.88%)
6. Arthralgia — 393 reports (9.71%)
7. Dizziness — 359 reports (8.87%)
8. Dyspnoea — 354 reports (8.74%)
9. Pain — 337 reports (8.32%)
10. Asthenia — 309 reports (7.63%)

Source database →

Frequently asked questions

Is Glucosamine/Chondroitin approved in United States?

Glucosamine/Chondroitin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Glucosamine/Chondroitin in United States?

Indus Hospital and Health Network is the originator. The local marketing authorisation holder may differ — check the official source linked above.